Dynavax Technologies Corporation

Merck Sharp + Dohme Corp.

US Government As Represented by the Secretary of the Army

Valneva Austria Gmbh

Trisalus Life Sciences, Inc.

Medigen Vaccine Biologics Corporation

Surefire Medical, Inc.

Robert S Janssen

Robert L Coffman

David Novack

Robert A Kastelein

Cristiana Guiducci

Andrew Evan Denker

Uyen Truong Phan

David Ross Kaufman

Svetlana Sadekova

Ying Yu

John Darren Campbell

Andreas Meinke

Robert Schlegl

Yu-Chi Wu

Jürgen Heindl-Wruss

Charles Chen

Chung-Chin Wu

Michael Möhlen

Christoph Reinisch

Lucy A Ward

Yi-Jiun Lin

Christian Taucher

Tsun-Yung Kuo

Meei-Yun Lin

Wai Kwan Chung

Paula Traquina

Andrew M Glenn

The present disclosure relates to immunogenic compositions comprising at least one() antigen, an aluminum salt adjuvant, and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response againstin a subject in need thereof. The present disclosure also relates to kits and methods using the immunogenic compositions, or two separate compositions which together comprise the antigen, the aluminum salt adjuvant, and the oligonucleotide.

Immunogenicity of a CpG-adjuvanted recombinant plague vaccine

The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.

Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.

Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer

Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

CpG-adjuvanted SARS-CoV-2 virus vaccine

Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer

Growing community of inventors

Berkeley, CA, United States of America

Robert S Janssen